Detalhe da pesquisa
1.
NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023.
J Natl Compr Canc Netw
; 21(7): 694-704, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37433432
2.
A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).
Future Oncol
; 18(40): 4465-4471, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36912078
3.
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Int J Cancer
; 149(12): 2063-2074, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34319586
4.
Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature.
J Natl Compr Canc Netw
; 19(1): 10-15, 2021 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33406492
5.
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(5): 541-565, 2021 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34030131
6.
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
Cancer
; 126(16): 3689-3697, 2020 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32525561
7.
A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma.
Br J Cancer
; 122(7): 963-970, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32037403
8.
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Oncologist
; 25(12): e1825-e1836, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32548867
9.
A Translational Hepatic Artery Infusion (HAI) Model for Hepatocellular Carcinoma in Woodchucks.
J Surg Res
; 251: 126-136, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32143057
10.
Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies.
Arch Biochem Biophys
; 661: 97-106, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30439360
11.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019.
J Natl Compr Canc Netw
; 17(4): 302-310, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30959462
12.
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Cancer
; 124(19): 3890-3899, 2018 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30299542
13.
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017.
J Natl Compr Canc Netw
; 15(5): 563-573, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28476736
14.
Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
Clin Adv Hematol Oncol
; 15 Suppl 4(4): 1-24, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28654022
15.
Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Curr Oncol Rep
; 18(1): 7, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26743514
16.
Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oncologist
; 20(7): 742-51, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26025932
17.
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.
Cancer
; 120(12): 1780-6, 2014 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24633933
18.
Occult primary, version 3.2014.
J Natl Compr Canc Netw
; 12(7): 969-74, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24994917
19.
Hepatobiliary cancers, version 2.2014.
J Natl Compr Canc Netw
; 12(8): 1152-82, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25099447
20.
Targeted therapy in gastrointestinal malignancies.
J Carcinog
; 13: 4, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24737952